TY - JOUR
T1 - Chronic Sleep Restriction While Minimizing Circadian Disruption Does Not Adversely Affect Glucose Tolerance
AU - Yuan, Robin K.
AU - Zitting, Kirsi Marja
AU - Duffy, Jeanne F.
AU - Vujovic, Nina
AU - Wang, Wei
AU - Quan, Stuart F.
AU - Klerman, Elizabeth B.
AU - Scheer, Frank A.J.L.
AU - Buxton, Orfeu M.
AU - Williams, Jonathan S.
AU - Czeisler, Charles A.
N1 - Funding Information:
Conflict of Interest: EK has received travel support from the Society of Reproductive Investigation, the Sleep Research Society, the National Sleep Foundation, the World Conference of Chronobiology, the Gordon Research Conferences, the Santa Fe Institute, and the DGSM; and consulting fees from Pfizer Inc., the Puerto Rico Trust, the National Sleep Foundation, Sanofi-Genzyme, and Circadian Therapeutics. FS has received lecture fees from Bayer HealthCare, Sentara HealthCare, Philips, Vanda Pharmaceuticals, and Pfizer Pharmaceuticals. SQ has received consulting fees from Jazz Pharmaceuticals and Best Doctors, and is a consultant to Whispersom. OB has received subcontracts to Penn State from Mobile Sleep Technologies/Proactive Life (National Science Foundation #1622766, National Institutes of Health R43AG056250, R44 AG056250), honoraria/travel support for lectures from Boston University, Boston College, Tufts School of Dental Medicine, Allstate, consulting fees from SleepNumber, and receives an honorarium for his role as the Editor in Chief (designate) of Sleep Health sleephealthjournal.org. CC reports grants from Cephalon Inc., Jazz Pharmaceuticals Plc., Inc., National Football League Charities, Optum, Philips Respironics, Inc., Regeneron Pharmaceuticals, ResMed Foundation, San Francisco Bar Pilots, Sanofi S.A., Sanofi-Aventis, Inc., Schneider Inc., Sepracor, Inc., Mary Ann and Stanley Snider via Combined Jewish Philanthropies, Sysco, Takeda Pharmaceuticals, Teva Pharmaceuticals Industries, Ltd., and Wake Up Narcolepsy; and personal fees from Bose Corporation, Boston Celtics, Boston Red Sox, Cephalon, Inc., Columbia River Bar Pilots, Ganésco Inc., Institute of Digital Media and Child Development, Klarman Family Foundation, Samsung Electronics, Quest Diagnostics, Inc., Teva Pharma Australia, Vanda Pharmaceuticals, Washington State Board of Pilotage Commissioners, Zurich Insurance Company, Ltd. In addition, CC holds a number of process patents in the field of sleep/circadian rhythms (e.g., photic resetting of the human circadian pacemaker) and holds an equity interest in Vanda Pharmaceuticals, Inc. Since 1985, CC has also served as an expert on various legal and technical cases related to sleep and/or circadian rhythms, including those involving the following commercial entities: Casper Sleep Inc., Comair/Delta Airlines, Complete General Construction Company, FedEx, Greyhound, HG Energy LLC, Purdue Pharma, LP, South Carolina Central Railroad Co., Steel Warehouse Inc., Stric-Lan Companies LLC, Texas Premier Resource LLC, and United Parcel Service (UPS). CC receives royalties from the New England Journal of Medicine; McGraw Hill; Houghton Mifflin Harcourt/Penguin; and Philips Respironics, Inc., for the Actiwatch-2 and Actiwatch-Spectrum devices. CC’s interests were reviewed and managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.
Funding Information:
We thank the research volunteers for their participation in the studies, Brigham and Women?s Hospital Center for Clinical Investigation (CCI) dietary, nursing and technical staff and the Division of Sleep and Circadian Disorders Sleep Core (Brandon Lockyer, Daniel Aeschbach), and Chronobiology Core (Jacob Medina, Alec Rader, Gina Daniels, Arick Wong, John Slingerland, Michael Harris, Julia Boudreau, Kyoko Hashimoto, John Wise, Divya Mohan, Audra Murphy, and Northeastern University co-ops) for their assistance with data collection. We thank the study recruiters, Gina Daniels, Alec Rader, and Jacob Medina. We also thank the following individuals for their contributions: Gail Adler, Jae Wook Cho, Cheryl Isherwood, Bruce Kristal, Ciaran McMullan, Connor O?Brian, and Joe Ronda.
Funding Information:
This study was supported by a grant from the National Institute on Aging (P01 AG009975) and a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK127254) and was conducted at the Brigham and Women’s Hospital Center for Clinical Investigation, part of Harvard Catalyst (Harvard Clinical and Translational Science Center) supported
Publisher Copyright:
Copyright © 2021 Yuan, Zitting, Duffy, Vujovic, Wang, Quan, Klerman, Scheer, Buxton, Williams and Czeisler.
PY - 2021/10/20
Y1 - 2021/10/20
N2 - Insufficient sleep, which has been shown to adversely affect metabolism, is generally associated with prolonged exposure to artificial light at night, a known circadian disruptor. There is growing evidence suggesting that circadian disruption adversely affects metabolism, yet few studies have attempted to evaluate the adverse metabolic effects of insufficient sleep while controlling for circadian disruption. We assessed postprandial glucose and insulin responses to a standard breakfast meal in healthy adults (n = 9) who underwent 3 weeks of chronic sleep restriction (CSR) in a 37-day inpatient study while minimizing circadian disruption by maintaining the same duration of light exposure each study day. We compared these results to findings from an earlier inpatient study which used a forced desynchrony (FD) protocol to assess the influence of 3 weeks of CSR combined with recurrent circadian disruption (RCD) on glycemic control in healthy adults (n = 21). CSR combined with RCD resulted in significantly elevated postprandial plasma glucose levels (p < 0.0001), while CSR with minimized circadian disruption had no adverse glycemic effects after 3 weeks of exposure (EXP). These results suggest that one mechanism by which sleep restriction impacts metabolism may be via concurrent circadian disruption.
AB - Insufficient sleep, which has been shown to adversely affect metabolism, is generally associated with prolonged exposure to artificial light at night, a known circadian disruptor. There is growing evidence suggesting that circadian disruption adversely affects metabolism, yet few studies have attempted to evaluate the adverse metabolic effects of insufficient sleep while controlling for circadian disruption. We assessed postprandial glucose and insulin responses to a standard breakfast meal in healthy adults (n = 9) who underwent 3 weeks of chronic sleep restriction (CSR) in a 37-day inpatient study while minimizing circadian disruption by maintaining the same duration of light exposure each study day. We compared these results to findings from an earlier inpatient study which used a forced desynchrony (FD) protocol to assess the influence of 3 weeks of CSR combined with recurrent circadian disruption (RCD) on glycemic control in healthy adults (n = 21). CSR combined with RCD resulted in significantly elevated postprandial plasma glucose levels (p < 0.0001), while CSR with minimized circadian disruption had no adverse glycemic effects after 3 weeks of exposure (EXP). These results suggest that one mechanism by which sleep restriction impacts metabolism may be via concurrent circadian disruption.
KW - chronic sleep restriction
KW - glucose tolerance
KW - insulin sensitivity
KW - metabolism
KW - recurrent circadian disruption
UR - http://www.scopus.com/inward/record.url?scp=85118641475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118641475&partnerID=8YFLogxK
U2 - 10.3389/fphys.2021.764737
DO - 10.3389/fphys.2021.764737
M3 - Article
AN - SCOPUS:85118641475
VL - 12
JO - Frontiers in Physiology
JF - Frontiers in Physiology
SN - 1664-042X
M1 - 764737
ER -